The class III antiarrhythmic effect of sotalol exerts a reverse use-dependent positive inotropic effect in the intact canine heart

被引:20
作者
Peralta, AO
John, RM
Gaasch, WH
Taggart, PI
Martin, DT
Venditti, FJ
机构
[1] Lahey Clin Med Ctr, Sect Cardiovasc Med, Burlington, MA 01805 USA
[2] Lahey Clin Med Ctr, Laser Res Lab, Burlington, MA 01805 USA
[3] UCL, London, England
关键词
D O I
10.1016/S0735-1097(00)00833-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES We sought to study the rate related effects of sotalol on myocardial contractility and to test the hypothesis that the class III antiarrhythmic effect of sotalol has a reverse use-dependent positive inotropic effect in the intact heart. BACKGROUND Antiarrhythmic drugs exert significant negative inotropic effects. Sotalol, a beta-adrenergic blocking agent with class III antiarrhythmic properties, may augment contractility by virtue of its ability to prolong the action potential duration (APD). METHODS In 10 anesthetized dogs, measurements of left ventricle (LV) peak (+)dP/dt and simultaneous endocardial action potentials were made during baseline conditions and after sequential administration of esmolol and sotalol. In addition, electrical and mechanical restitution curves were constructed at a basic pacing cycle length of 600 ms by introducing a test pulse of altered cycle length ranging from 200 ms to 2,000 ms. RESULTS In the steady state pacing experiments, sotalol prolonged the APD in a reverse use-dependent manner; such an effect was not seen with esmolol. At cycle lengths exceeding 400 ms, LV (+)dP/dt was significantly higher with sotalol than it was with esmolol. There was a direct relation between APD and LV (+)dP/dt with sotalol (r = 0.46, p < 0.001), but there was no significant relation between APD and LV (+)dP/dt with esmolol (r = 0.27, p = NS). Results in the single beat (restitution) studies were qualitatively similar to the steady stare results; APD (at cycle length >400 ms) and LV (+)dP/dt (at cycle length >600 ms) were significantly higher with sotalol than they were with esmolol. CONCLUSIONS The reverse use-dependent prolongation of APD by sotalol is associated with a positive inotropic effect. (J Am Coll Cardiol 2000;36:1404-10) (C) 2000 by the American College of Cardiology.
引用
收藏
页码:1404 / 1410
页数:7
相关论文
共 23 条
[1]   A COMPARATIVE STUDY OF SOME CARDIOVASCULAR EFFECTS OF SOTALOL (MJ 1999) AND PROPRANOLOL [J].
ABERG, G ;
DZEDIN, T ;
LUNDHOLM, L ;
OLSSON, L ;
SVEDMYR, N .
LIFE SCIENCES PART 1 PHYSIOLOGY AND PHARMACOLOGY AND PART 2 BIOCHEMISTRY GENERAL AND MOLECULAR BIOLOGY, 1969, 8 (7P1) :353-&
[2]  
ANGARAN DM, 1986, CLIN PHARMACY, V5, P288
[3]   MECHANISM OF RELEASE OF CALCIUM FROM SARCOPLASMIC-RETICULUM OF GUINEA-PIG CARDIAC-CELLS [J].
BEUCKELMANN, DJ ;
WIER, WG .
JOURNAL OF PHYSIOLOGY-LONDON, 1988, 405 :233-255
[4]   KINETICS OF ONSET OF RATE-DEPENDENT EFFECTS OF CLASS-I ANTI-ARRHYTHMIC DRUGS ARE IMPORTANT IN DETERMINING THEIR EFFECTS ON REFRACTORINESS IN GUINEA-PIG VENTRICLE, AND PROVIDE A THEORETICAL BASIS FOR THEIR SUBCLASSIFICATION [J].
CAMPBELL, TJ .
CARDIOVASCULAR RESEARCH, 1983, 17 (06) :344-352
[5]   Action potential duration modulates calcium influx, Na+-Ca2+ exchange, and intracellular calcium release in rat ventricular myocytes [J].
Clark, RB ;
Bouchard, RA ;
Giles, WR .
SODIUM-CALCIUM EXCHANGE: PROCEEDINGS OF THE THIRD INTERNATIONAL CONFERENCE, 1996, 779 :417-429
[7]   ELECTRICAL AND MECHANICAL RESTITUTION OF THE HUMAN-HEART AT DIFFERENT RATES OF STIMULATION [J].
FRANZ, MR ;
SCHAEFER, J ;
SCHOTTLER, M ;
SEED, WA ;
NOBLE, MIM .
CIRCULATION RESEARCH, 1983, 53 (06) :815-822
[8]   EFFECTS OF SOTALOL AND PROPRANOLOL ON CONTRACTILE FORCE AND ATRIOVENTRICULAR CONDUCTION TIME OF DOG HEART IN SITU [J].
HOFFMANN, RP ;
GRUPP, G .
DISEASES OF THE CHEST, 1969, 55 (03) :229-&
[9]   POSITIVE AND NEGATIVE INOTROPIC EFFECTS OF DL-SOTALOL AND D-SOTALOL IN FAILING AND NONFAILING HUMAN MYOCARDIUM UNDER PHYSIOLOGICAL EXPERIMENTAL CONDITIONS [J].
HOLUBARSCH, C ;
SCHNEIDER, R ;
PIESKE, B ;
RUF, T ;
HASENFUSS, G ;
FRAEDRICH, G ;
POSIVAL, H ;
JUST, H .
CIRCULATION, 1995, 92 (10) :2904-2910
[10]  
KOMEICHI K, 1990, EUR J PHARMACOL, V187, P313